Patents by Inventor Masaomi Tajimi
Masaomi Tajimi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080045546Abstract: This invention relates to tetrahydro-naphthalene and urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene and urea derivatives of the present invention have vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).Type: ApplicationFiled: October 2, 2004Publication date: February 21, 2008Inventors: Axel Bouchon, Nicole Diedrichs, Achim Hermann, Klemens Lustig, Heinrich Meier, Josef Pemerstorfer, Elke Reissmuller, Muneto Mogi, Takeshi Yura, Hiroshi Fujishima, Masanori Seki, Yuji Koriyama, Kayo Yasoshima, Keiko Misawa, Masaomi Tajimi, Noriyuki Yammoto, Klaus Urbahns, Fumihiko Hayashi, Yasuhiro Tsukimi, Jang Gupta
-
Publication number: 20070213363Abstract: This invention relates to tetrahydro-quinolinylurea derivatives and salts thereof which are useful as active ingredi- ents of pharmaceutical preparations. The tetrahydro-quinolinylurea derivative of the present invention has vanilloid receptor (VR I) C antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for =the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor oeractivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pul- monary (or airways) disease (COPD).Type: ApplicationFiled: October 26, 2004Publication date: September 13, 2007Applicant: Bayer HealthCare AGInventors: Axel Bouchon, Nicole Diedrichs, Achim Hermann, Klemens Lustig, Heinrich Meier, Josef Pernerstorfer, Elke Reissmuller, Mogi Muneto, Hiroshi Fujishima, Masaomi Tajimi, Noriyuki Yamamoto
-
Publication number: 20070167458Abstract: This invention relates to a hydroxy-tetrahydro-naphthalene or an urea derivative formula (I) and salts thereof which are useful as active ingredients of pharmaceutical preparations, wherein A represents formula (II) or (III) wherein # represents the connection position to the molecule and Q1a, Q2a, Q3a and Q4a are defined, and E represents formula (IV) or (V) wherein # represents the connection position to the molecule and Q1b, Q2b, Q3b, Q4b, Q5b, R1b, na, ma, Xa and Ra are defined.Type: ApplicationFiled: September 22, 2004Publication date: July 19, 2007Applicant: BAYER HEALTHCARE AGInventors: Axel Bouchon, Nicole Diedrichs, Achim Hermann, Klemens Lustig, Heinrich Meier, Josef Pernerstorfer, Elke Reissmuller, Jean De Vry, Muneto Mogi, Klaus Urbahns, Takeshi Yura, Hiroshi Fujishima, Masaomi Tajimi, Noriyuki Yamamoto, Hiroaki Yuasa, Jang Gupta, Yasuhiro Tsukimi, Fumihiko Hayashi
-
Publication number: 20070027187Abstract: This invention relates to hydroxy-tetrahydro-naphthalenylurea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The hydroxy-tetrahydro-naphthalenylurea derivatives of the present invention have an excellent activity as VR1 antagonist and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.Type: ApplicationFiled: February 5, 2004Publication date: February 1, 2007Applicant: Bayer HealthCare AGInventors: Takeshi Yura, Muneto Mogi, Hiroshi Fujishima, Klaus Urbahns, Tsutomu Masuda, Yasuhiro Tsukimi, Masaomi Tajimi, Noriyuki Yamamoto, Nagahiro Yoshida, Toshiya Moriwaki
-
Publication number: 20060183753Abstract: The present invention relates to the use of 2,5-diamidoindole derivatives for the preparation of medicaments for treating urological disorders in humans and/or animals.Type: ApplicationFiled: December 6, 2003Publication date: August 17, 2006Applicant: Bayer HealthCare AGInventors: Jens Erguden, Thomas Krahn, Christian Schroder, Johannes Stasch, Stefan Weigand, Hanno Wild, Michael Brands, Stehan Siegel, Dirk Heimbach, Jorg Keldenich, Masaomi Tajimi, Hiroko Takagi
-
Patent number: 7091242Abstract: The present invention relates to compounds of the general formula (I), processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment of inflammatory diseases.Type: GrantFiled: October 8, 2001Date of Patent: August 15, 2006Assignee: Bayer AktiengesellschaftInventors: Thomas Rölle, Thomas Lehmann, Markus Albers, Gerhard Hessler, Gerhard Müller, Rüdiger Fischer, Masaomi Tajimi, Karl Ziegelbauer, Kevin Bacon, Haruki Hasegawa, Hiromi Okigami
-
Publication number: 20060166989Abstract: The present invention relates to 2-naphthamides, which are useful as an active ingredient of pharmaceutical preparations. The 2-naphthamides of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor activity. Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benign prostatic hypertrophy (BPH), pro-statitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity.Type: ApplicationFiled: May 30, 2003Publication date: July 27, 2006Applicant: Bayer Healthcare AGInventors: Makoto Shimazaki, Osamu Sakurai, Toshiki Murata, Klaus Urbahns, Noriyuki Yamamoto, Satoru Yoshikawa, Masaomi Umeda, Masaomi Tajimi, Tsutomu Masuda, Takuya Shintani, Haruka Shimizu
-
Publication number: 20060135613Abstract: The present invention relates to carboxamides which are useful as an active ingredient of pharmaceutical preparations. The carboxamides of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity. Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity.Type: ApplicationFiled: June 12, 2003Publication date: June 22, 2006Applicant: Bayer Healthcare AGInventors: Makoto Shimazaki, Osamu Sakurai, Kanako Hirai, Klaus Urbahns, Noriyuki Yamamoto, Satoru Yoshikawa, Masaomi Umeda, Masaomi Tajimi
-
Publication number: 20060135505Abstract: This invention relates to tetrahydro-naphthalene derivatives of formula (I) in which the variable groups are as defined in the specification and claims, and tautomeric and stereoisomeric forms and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD. The compounds, pharmaceutical compositions containing them, and methods of treatment using them are disclosed and claimed.Type: ApplicationFiled: November 28, 2003Publication date: June 22, 2006Applicant: Bayer Healthcare AGInventors: Masaomi Tajimi, Toshio Kokubo, Masahiro Shiroo, Yasuhiro Tsukimi, Takeshi Yura, Klaus Urbahns, Noriyuki Yamamoto, Muneto Mogi, Hiroshi Fujishima, Tsutomu Masuda, Nagahiro Yoshida, Toshiya Moriwaki
-
Patent number: 7064229Abstract: The present invention relates to compounds of the general formula (I), processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment of inflammatory diseasesType: GrantFiled: June 24, 2002Date of Patent: June 20, 2006Assignee: Bayer Healthcare AGInventors: Thomas Rolle, Thomas Lehmann, Markus Albers, Gerhard Muller, Gerhard Hessler, Rudiger Fischer, Masaomi Tajimi, Karl Ziegelbauer, Kevin Bacon, Haruki Hasegawa, Hiromi Okigami
-
Publication number: 20060128704Abstract: This invention relates to tetrahydro-naphthalene derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. They have the general formula (I) in which R1 represents hydrogen or C1-6 alkyl, and X represents —N(H)Y1, —N(H)—C1-6 alkylene Y1, biphenyl or C1-6 alkyl substituted by biphenyl, and the group Y1 is an optionally substituted biphenyl. The tetrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontinence, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.Type: ApplicationFiled: November 28, 2003Publication date: June 15, 2006Applicant: Bayer HealthCare AGInventors: Masaomi Tajimi, Toshio Kokubo, Masahiro Shiroo, Yasuhiro Tsukimi, Takeshi Yura, Klaus Urbahns, Noriyuki Yamamoto, Muneto Mogi, Hiroshi Fujishima, Tsutomu Masuda, Nagahiro Yoshida, Toshiya Moriwaki
-
Publication number: 20050222247Abstract: This invention relates to chroman derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The chroman derivatives of the present invention have an excellent activity as BETA 3 antagonists and are useful for the prophylaxis and treatment of diseases associated with BETA 3 activity, in particular for the treatment of urological disorder or disease, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor oeractivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; and inflammatory disorders, such as asthma and COPD.Type: ApplicationFiled: November 23, 2004Publication date: October 6, 2005Applicant: Bayer HealthCare AGInventors: Stephen Boyer, Kentaro Hashimoto, Thomas Rolle, Peter Sandner, Beatrix Stelte-Ludwig, Hanna Tinel, Kerstin Henninger, Arnel Concepcion, Osamu Sakurai, Kanako Hirai, Tadashi Inoue, Yuki Mochizuki, Noriko Nunami, Masaomi Tajimi, Noriyuki Yamamoto, Yasuhiro Tsukimi
-
Publication number: 20050176010Abstract: Reagents which regulate human transient receptor potential channel and reagents which bind to human transient receptor potential channel gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, urinary incontinence, overactive bladder, benign prostatic hyperplasia, lower urinary tract syndromes, and CNS disorders.Type: ApplicationFiled: April 10, 2003Publication date: August 11, 2005Applicant: Bayer HealthCare AGInventors: Masahiro Shiroo, Noriyuki Yamamoto, Fumihiko Hayashi, Johannes Floeckner, Peter Reinemer, Jeffrey Encinas, Shinichi Watanabe, Masaomi Tajimi, Toshio Kokubo
-
Publication number: 20050154230Abstract: This invention relates to urea derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The urea derivatives of the present invention has an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and/or inflammatory disorders.Type: ApplicationFiled: December 13, 2002Publication date: July 14, 2005Applicant: Bayer HealthCare AGInventors: Takeshi Yura, Muneto Mogi, Yuka Ikegami, Tsutomu Masuda, Toshio Kokubo, Klaus Urbahns, Nagahiro Yoshida, Makiko Marumo, Masahiro Shiroo, Masaomi Tajimi, Keisuke Takeshita, Toshiya Moriwaki, Yasuhiro Tsukimi
-
Publication number: 20050119304Abstract: A medicament which contains a urea derivative or a salt thereof as an active ingredient is disclosed. The medicament has an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and/or inflammatory disorders.Type: ApplicationFiled: December 13, 2002Publication date: June 2, 2005Inventors: Takeshi Yura, Muneto Mogi, Yuka Ikegami, Tsutomu Masuda, Toshio Kokubo, Klaus Urbahns, Nagahiro Yoshida, Makiko Marumo, Masahiro Shiroo, Masaomi Tajimi, Keisuke Takeshita, Toshiya Moriwaki, Yasuhiro Tsukimi
-
Publication number: 20050054582Abstract: The present invention relates to compounds of the general formula (I), their preparation and use as pharmaceutical compositions asintegrin antagonists, especially as ?4? and/or ?4?7 ?and/or ?9?1 intergrin antagonists and in particular for the production of pharmaceutical compositions suitable for the inhibition or the prevention of cell adhesion and cell-adhesion mediated disorders. Examples are the treatment and the prophylaxis of atherosclerosis, asthma, chronic obstructive pulmonary disease (COPD), allergies, diabetes, inflammatory bowel disease, multiple sclerosis, myocardial ischemia, rheumatoid arthritis, transplant rejection and other inflammatory, autoimmune and immune disorders.Type: ApplicationFiled: September 20, 2002Publication date: March 10, 2005Inventors: Thomas Lehmann, Markus Albers, Thomas Rolle, Gerhard Hessler, Gerhard Hessler, Masaomi Tajimi, Karl Ziegelbauer, Hiromi Okigami, Kevin Bacon, Haruki Hasegawa
-
Publication number: 20040259875Abstract: An amine derivative, its tautomeric or stereoisomeric form, or a salt thereof which has vanilloid receptor 1 (VR1) antagonistic activity, is disclosed. The amine derivative has an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and/or inflammatory disorders.Type: ApplicationFiled: July 26, 2004Publication date: December 23, 2004Inventors: Takeshi Yura, Muneto Mogi, Yuka Ikegami, Tsutomu Masuda, Toshio Kokubo, Klaus Urbahns, Timothy B Lowinger, Nagahiro Yoshida, Joachim Freitag, Heinrich Meier, Reilinde Nopper, Makiko Marumo, Masahiro Shiroo, Masaomi Tajimi, Keisuke Takeshita, Toshiya Moriwaki, Yasuhiro Tsukimi
-
Publication number: 20040254157Abstract: The present invention relates to compounds of the general formula (I), processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment of inflammatory diseases.Type: ApplicationFiled: August 4, 2004Publication date: December 16, 2004Inventors: Thomas Rlle, Thomas Lehmann, Markus Albers, Gerhard Muller, Gerhard Hessler, Rudiger Fischer, Masaomi Tajimi, Karl Ziegelbauer, Kevin Bacon, Haruki Hasegawa, Hiromi Okigami
-
Publication number: 20040229859Abstract: The present invention relates to compounds of the general formula (I), 1Type: ApplicationFiled: May 28, 2004Publication date: November 18, 2004Applicant: Bayer AktiengesellschaftInventors: Markus Albers, Thomas Lehmann, Thomas Rolle, Gerhard Muller, Gerhard Hessler, Masaomi Tajimi, Karl Ziegelbauer, Hiromi Okigami, Haruki Hasegawa
-
Patent number: 6794386Abstract: The present invention relates to a compound of the general formula (I), wherein R1 together with the C atom to which it is attached, and R2 together with the N atom to which it is attached, form a piperidinyl ring; X represents a bond, oxygen or —NR12—; and Y represents oxygen; pharmaceutical compositions containing such a compound, as well as the use of such a compound for the production of pharmaceutical compositions, and for the treatment of inflammatory, auto-immune and immune diseases.Type: GrantFiled: November 19, 2002Date of Patent: September 21, 2004Assignee: Bayer AktiengesellschaftInventors: Markus Albers, Thomas Lehmann, Thomas Rölle, Gerhard Müller, Gerhard Hessler, Masaomi Tajimi, Karl Ziegelbauer, Hiromi Okigami, Haruki Hasegawa